← All themes

GLP-1 & Obesity

GLP-1 medicines treat obesity and diabetes, and have grown into one of the largest drug categories ever launched. Their reach extends past medicine, because a change in how much people eat moves whole consumer industries.

92 stocks

Obesity Second-Order Effects

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Pfizer PFE $166B	1,861	+118	+7%	$138B
2	2 Amgen AMGN $230B	1,341	+118	+10%	$98.5B
3	3 Eli Lilly LLY $1.08T	1,130	+88	+8%	$58.1B
4	4 McKesson MCK $114B	889	+71	+9%	$41.3B
5	5 Becton Dickinson BDX $51.5B	885	+38	+4%	$22.9B
6	6 Teva Pharmaceutical Industries Limited TEVA $47.5B	822	+49	+6%	$30.2B
7	7 Conagra Brands CAG $6.61B	648	+16	+3%	$11.3B
8	8 Regeneron Pharmaceuticals REGN $80.1B	512	+38	+8%	$29.6B
9	9 Novo Nordisk NVO $168B	501	+31	+7%	$8.53B
10	10 DaVita DVA $11.5B	496	+22	+5%	$13.7B
11	11 AstraZeneca AZN $251B	404	+2	+0.5%	$6.57B
12	12 ResMed RMD $33.1B	309	+8	+3%	$4.2B
13	13 Herbalife HLF $1.49B	242	-13	-5%	$3.82B
14	14 Accendra Health ACH $24.1M	229	+5	+2%	$2.06B
15	15 West Pharmaceutical WST $26.4B	225	+12	+6%	$3.5B
16	16 MannKind Corp MNKD $971M	180	+4	+2%	$528M
17	17 Opko Health OPK $1.02B	176	-7	-4%	$780M
18	18 Dr. Reddy's Laboratories RDY $10.6B	168	+9	+6%	$1.3B
19	19 DELISTED WW International WW	157	+11	+8%	$1.55B
20	20 Tootsie Roll Industries TR $2.87B	152	+8	+6%	$405M
21	21 Fresenius Medical Care FMS $11.5B	143	+13	+10%	$453M
22	ARNA 22 DELISTED Arena Pharmaceuticals Inc ARNA	129	+8	+7%	$401M
23	23 Medifast MED $132M	124	0	0%	$348M
24	24 Lexicon Pharmaceuticals LXRX $712M	123	+19	+18%	$627M
25	25 DELISTED CATALENT, INC. CTLT	94	+14	+18%	$3.27B